HC Wainwright & Co. Reiterates Buy on Citius Pharma, Maintains $4 Price Target

Benzinga · 05/31 17:06
HC Wainwright & Co. analyst Vernon Bernardino reiterates Citius Pharma (NASDAQ:CTXR) with a Buy and maintains $4 price target.